Overview

A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase Ib/II, multicenter, randomized, single-masked, sham-injection-controlled study of safety, tolerability, and evidence of activity of FCFD4514S intravitreal injections administered monthly or every other month in patients with geographic atrophy.
Phase:
Phase 2
Details
Lead Sponsor:
Genentech, Inc.